Progressive Fibrosing Interstitial Lung Disease Treatment Market Size in the 7MM was USD 4,205 Million which is expected to grow by 2032, estimates DelveInsight | Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd, Pliant Therapeu

DelveInsight's 'Progressive Fibrosing Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of the Progressive Fibrosing Interstitial Lung Disease, historical and forecasted epidemiology as well as the Progressive Fibrosing Interstitial Lung Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Discover Key Insights into the Progressive Fibrosing Interstitial Lung Disease Market with DelveInsight's In-Depth Report @ Progressive Fibrosing Interstitial Lung Disease Market Size- https://www.delveinsight.com/sample-request/progressive-fibrosing-interstitial-lung-disease-pfild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Progressive Fibrosing Interstitial Lung Disease Market Report
• In February 2025:- Bristol-Myers Squibb:- The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.
• In February 2025:- Avalyn Pharma Inc.:- This is a randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of AP01 (pirfenidone solution for inhalation) versus placebo on top of standard of care in participants with PPF over 52 weeks. Up to 300 eligible participants will be randomized to 1 of 3 treatment arms: AP01 high dose, AP01 low dose, or placebo.
• In February 2025:- Boehringer Ingelheim:- The primary objective is to evaluate the incidence of adverse drug reactions (focus on hepatic function disorders) of Ofev Capsules under the real world setting in patients with Chronic fibrosing Interstitial Lung Diseases with a progressive phenotype (PF-ILD).
• In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease in the 7MM were 322,197 cases in 2021.
• The highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease were accounted by the US in 2021 (166,393 cases), which are expected to show a rise in the future.
• Among the European countries, Germany had the highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease with 31,807 cases, followed by the United Kingdom, which had diagnosed cases of 25,446 in 2021. On the other hand, Spain had the lowest diagnosed population (17,834 cases).
• Japan had 31,542 total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease for in 2021, accounting for approximately 10% in the 7MM.
• The leading Progressive Fibrosing Interstitial Lung Disease Companies such as Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB, and others.
• Progressive Fibrosing Interstitial Lung Disease Therapies such as BMS-986278, AP01, HEC585 Dose B, ENV-101, Nintedanib, Pirfenidone and others.

Stay ahead in the Progressive Fibrosing Interstitial Lung Disease Therapeutics Market with DelveInsight's Strategic Report @ Progressive Fibrosing Interstitial Lung Disease Market Outlook- https://www.delveinsight.com/sample-request/progressive-fibrosing-interstitial-lung-disease-pfild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Progressive Fibrosing Interstitial Lung Disease Epidemiology Segmentation in the 7MM
• Total Progressive Fibrosing Interstitial Lung Disease Prevalent Cases
• Total Progressive Fibrosing Interstitial Lung Disease Diagnosed Prevalent Cases
• Progressive Fibrosing Interstitial Lung Disease Type-specific Diagnosed Prevalent Cases
• Total Progressive Fibrosing Interstitial Lung Disease Diagnosed Prevalent cases

Download the report to understand which factors are driving Progressive Fibrosing Interstitial Lung Disease epidemiology trends @ Progressive Fibrosing Interstitial Lung Disease Prevalence- https://www.delveinsight.com/sample-request/progressive-fibrosing-interstitial-lung-disease-pfild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Progressive Fibrosing Interstitial Lung Disease Emerging Drugs
• BI 1015550: Boehringer Ingelheim
BI 1015550 is an investigational, oral, phosphodiesterase 4B (PDE4B) inhibitor with combined antifibrotic and anti-inflammatory effects being developed by Boehringer Ingelheim. It has the potential to address both pulmonary fibrosis - an irreversible scarring of lung tissue that negatively impacts lung function - and inflammation associated with Progressive Fibrosing Interstitial Lung Disease (ILDs). BI 1015550 represents the first molecule in the class of PDE4B inhibitors that is being studied for IPF and other progressive fibrosing ILDs. Breakthrough Therapy Designation was granted to BI 1015550 in February 2022 for the treatment of idiopathic pulmonary fibrosis (IPF) by the US Food and Drug Administration (FDA).

• Pamrevlumab: FibroGen
FibroGen is developing pamrevlumab (also known as FG-3019), an intravenously administered, first-in-class, fully-humanized monoclonal antibody that inhibits the activity of connective tissue growth factor activity, or CTGF, a critical mediator in the progression of fibrosis and related serious diseases. Other than IPF, FibroGen is also evaluating Pamrevlumab in Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD), and locally advanced unresectable pancreatic cancer (LAPC). Furthermore, as stated by the company, the drug demonstrated the potential for stabilization of disease and reversal of lung fibrosis in some patients.

Progressive Fibrosing Interstitial Lung Disease Market Outlook
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) consist of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation and earlier mortality. ILD and its progressing forms, form a substantial proportion of disabling chronic lung disease leading to significant morbidity and mortality. From the current treatment market scenario, Nintedanib is the only approved treatment in the chronic fibrotic ILDs in the 7MM. Myriads of patients with PF-ILDs are currently orphan of evidence-based treatments and are left with options of receiving corticosteroids and/or off-label immunosuppressive therapies with variable outcomes and are the mainstay of treatment in PF-ILDs. These unmet treatment gaps accentuates the launch of emerging therapies.

Get In-Depth Knowledge on Progressive Fibrosing Interstitial Lung Disease Market Trends and Forecasts with DelveInsight @ Progressive Fibrosing Interstitial Lung Disease Treatment Market- https://www.delveinsight.com/sample-request/progressive-fibrosing-interstitial-lung-disease-pfild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Progressive Fibrosing Interstitial Lung Disease Drugs Uptake
The drug chapter of the Progressive Fibrosing Interstitial Lung Disease pipeline report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Acute Pulmonary Embolism.

Progressive Fibrosing Interstitial Lung Disease Companies
Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB and others.

Unlock Strategic Insights with DelveInsight's Comprehensive Progressive Fibrosing Interstitial Lung Disease Market Report @ Progressive Fibrosing Interstitial Lung Disease Market Drivers and Barriers- https://www.delveinsight.com/sample-request/progressive-fibrosing-interstitial-lung-disease-pfild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Progressive Fibrosing Interstitial Lung Disease Market Report
• Coverage- 7MM
• Progressive Fibrosing Interstitial Lung Disease Companies- Boehringer Ingelheim, Bristol-Myers Squibb, FibroGen, Hoffmann-La Roche Ltd, Pliant Therapeutics, Inc., United Therapeutics, Vicore Pharma AB, and others.
• Progressive Fibrosing Interstitial Lung Disease Therapies- BMS-986278, AP01, HEC585 Dose B, ENV-101, Nintedanib, Pirfenidone and others.
• Progressive Fibrosing Interstitial Lung Disease Market Dynamics: Progressive Fibrosing Interstitial Lung Disease Market Drivers and Barriers
• Progressive Fibrosing Interstitial Lung Disease Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Progressive Fibrosing Interstitial Lung Disease Drugs in development @ Progressive Fibrosing Interstitial Lung Disease Clinical Trials Assessment- https://www.delveinsight.com/sample-request/progressive-fibrosing-interstitial-lung-disease-pfild-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Report Introduction
3. Progressive Fibrosing Interstitial Lung Diseases (PF-ILD) Market Overview at a Glance
4. Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Market: Future Perspective
5. Executive Summary of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD)
6. Key Events
7. Disease Background and Overview: Progressive-Fibrosing Interstitial Lung Disease (PF-ILD)
8. Epidemiology and Patient Population
9. Patient Journey
10. Marketed Therapies
11. Emerging Drugs
12. Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Seven Major Market Analysis
13. Key Opinion Leaders' Views
14. Market Drivers
15. Market Barriers
16. SWOT Analysis
17. Unmet Needs
18. Reimbursement and Market Access
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

List of Top Selling Market Research Reports in 2025

Intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Phototherapies for psoriasis market- https://www.delveinsight.com/report-store/chronic-plaque-psoriasis-market
Vascular access devices market- https://www.delveinsight.com/report-store/vascular-access-device-market
NK cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Ventral hernia market- ttps://www.delveinsight.com/report-store/hernia-repair-devices-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market
Total knee arthroplasty market- https://www.delveinsight.com/report-store/knee-reconstruction-devices-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-and-adhesives-market
Baricose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Pouchitis market- https://www.delveinsight.com/report-store/pouchitis-market
Diabetic wound market- https://www.delveinsight.com/report-store/diabetic-wounds-market
Healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
Transcatheter treatment market- https://www.delveinsight.com/report-store/transcatheter-treatment-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Overactive bladder syndrome market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Chronic neuropathic pain market- https://www.delveinsight.com/report-store/chronic-neuropathic-pain-market
Microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.